Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed/Refractory B-cell NHL
NCT02992522Phase 1Active, not recruiting
- Start
- Feb 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax and lenalidomide in B-cell non-Hodgkin lymphoma. Primary endpoint: Maximum Tolerated Dose up to 28 days. Started Feb 2017; status: active, not recruiting.
02
Drugs
venetoclaxlenalidomide
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02992522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992522.